Corvus Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
CRVS$11.35+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets · · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $4,576 | | $8,740 | ||
| Marketable securities | | 52,174 | | 43,224 | ||
| Accounts receivable - related party | | 37 | | 75 | ||
| Prepaid and other current assets | | 1,427 | | 2,368 | ||
| Total current assets | | 58,214 | | 54,407 | ||
| Property and equipment, net | | 220 | | 151 | ||
| Operating lease right-of-use asset | | | 839 | | | 1,177 |
| Investment in Angel Pharmaceuticals | | | 10,991 | | | 12,540 |
| Other assets | | | 855 | | | 632 |
| Total assets | | $71,119 | | $68,907 | ||
| | | | | | | |
| Liabilities and Stockholders’ Equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $2,491 | | $2,582 | ||
| Operating lease liability | | | 403 | | | 185 |
| Accrued and other liabilities | | 6,486 | | 3,725 | ||
| Warrant liability | | | — | | | 28,910 |
| Total current liabilities | | 9,380 | | 35,402 | ||
| Operating lease liability | | | 534 | | | 937 |
| Total liabilities | | 9,914 | | 36,339 | ||
| Commitments and contingencies (Note 15) | | | | | ||
| Stockholders’ equity: | | | | | ||
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued and outstanding at each of December 31, 2025 and December 31, 2024 | | | — | | | — |
| Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2025 and December 31, 2024; 74,696,629 and 67,899,779 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | | 7 | | 7 | ||
| Additional paid-in capital | | 474,387 | | 430,859 | ||
| Accumulated other comprehensive loss | | (896) | | (1,288) | ||
| Accumulated deficit | | (412,293) | | (397,010) | ||
| Total stockholders’ equity | | 61,205 | | 32,568 | ||
| Total liabilities and stockholders’ equity | | $71,119 | | $68,907 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.